articleLung CancerJan 25, 2017Closed access

Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer

SBStephen BagleySKShawn KothariCACharu AggarwalJBJoshua BaumlEAEvan Alley

University of Pennsylvania

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

528
total citations
FWCI
26.86
Percentile
100%
References
39
Citations per year

Authors

19

Topics & keywords

Topics
Keywords
  • Medicine
  • Nivolumab
  • Internal medicine
  • Ipilimumab
  • Proportional hazards model
  • Neutrophil to lymphocyte ratio
  • Lung cancer
  • Cohort
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.